Several studies had confirmed that a high TIL level predicted response to neoadjuvant chemotherapy (NAC) in all molecular subtypes and was also associated with a survival benefit in human epidermal growth factor receptor 2(HER2)-positive and triple-negative breast cancer (TNBC). Here, ERBB2 is linked to triple-negative breast carcinoma.